Form 4: Pliant Therapeutics Director Acquires Stock Options

Director David E I Pyott acquired stock options in Pliant Therapeutics, Inc. on June 13, 2024.

Summary

• On June 13, 2024, David E I Pyott, a director of Pliant Therapeutics, Inc., acquired options to purchase 26,764 shares of common stock at an exercise price of $13.06.
• These options vest quarterly, with 25% vesting on the first day of each calendar quarter for three quarters following the grant date.
• The remaining 25% vests on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service as a director.
• Following the transaction, Pyott beneficially owns 26,764 shares of Pliant Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, and while insider ownership is generally viewed positively, this is just a standard option grant.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a continued commitment from the director to the company.

Industry Context

This is a standard SEC Form 4 filing, reflecting a transaction by a company insider. Such filings are common in the biopharmaceutical industry and provide transparency regarding the holdings and transactions of company executives and directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates